Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events

American Journal of Cardiology

Volumn 92, Issue 1, 2003, Pages 79-81

  Foley, Kathleen A ^b   Simpson Jr , Ross J ^a   Crouse III, John R ^b   Weiss, Thomas W ^b   Markson, Leona E ^b   Alexander, Charles M ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; ETHNOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; STATISTICAL ANALYSIS; TITRIMETRY;

EID: 0037524291     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00474-0     Document Type: Article

References (14)

1. Andrews T.C., Ballantyne C.M., Hsia J.A., Kramer J.H. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med. 111:2001;185-191.
2. Davidson M., Ma P., Stein E., Gotto A., Raza A., Chitra R., Hutchison H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 89:2002;268-275.
3. Vicari R., Wan G., Aura M., Alexander C., Markson L., Teutsch S. Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. Arch Fam Med. 9:2000;898-905.
4. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
5. Diabetes Care. 22:(Suppl 1):1999;S56-S59.
6. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease 2001 update . Circulation. 104:2001;1577-1579.
7. Muls E., De Backer G., Brohet C., Heller F. The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals the LIPI-GOAL trial . Acta Cardiologica. 56:2001;109-114.
8. Garmendia F., Brown A.S., Reiber I., Adams P.C. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Cur Med Res Opin. 16:2000;208-219.
9. Hunninghake D., Bakker-Arkema R.G., Wigand J.P., Drehobl M., Schrott H., Early J.L., Abdallah P., McBride S., Black D.M. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 47:1998;349-356.
10. Sueta C.A., Chowdhury M., Boccuzzi S., Smith S.C., Alexander C.M., Londhe A., Lulla A., Simpson R.J. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307.
11. Pearson T., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project. Arch Intern Med. 160:2000;459-467.
12. Fonarow G., Gawlinksi A., Moughrabi S., Tillisch J. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 87:2001;819-822.
13. Pearson T., Feinberg W. Behavioral issues in the efficacy versus effectiveness of pharmacological agents in the prevention of cardiovascular disease. Ann Behav Med. 19:1997;230-238.
14. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 312:1996;1215-1218.